

(19) AUSTRALIAN PATENT OFFICE

- (54) Title
Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane
compounds for treating urinary incontinence
- (51)⁶ International Patent Classification(s)
A61K 31/13 060408BMEP
(2006.01) PCT/EP01/1391
A61K 31/13 7
20060101AFI20
- (21) Application No: 2002223688 (22) Application Date: 2001.11.28
- (87) WIPO No: W002/43714
- (30) Priority Data
- | (31) Number | (32) Date | (33) Country |
|--------------|------------|--------------|
| 100 59 413.1 | 2000.11.30 | DE |
- (43) Publication Date : 2002.06.11
(43) Publication Journal Date : 2002.08.15
- (71) Applicant(s)
Gruenenthal GmbH
- (72) Inventor(s)
Christoph, Thomas; Friderichs, Elmar
- (74) Agent/Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market
Street, Sydney, NSW, 2000

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
6. Juni 2002 (06.06.2002)

PCT

(10) Internationale Veröffentlichungsnummer
WO 02/43714 A2

- (51) Internationale Patentklassifikation⁷: A61K 31/00
- (21) Internationales Aktenzeichen: PCT/EP01/13917
- (22) Internationales Anmeldedatum:
28. November 2001 (28.11.2001)
- (25) Einreichungssprache: Deutsch
- (26) Veröffentlichungssprache: Deutsch
- (30) Angaben zur Priorität:
100 59 413.1 30. November 2000 (30.11.2000) DE
- (71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von
US): GRÜNENTHAL GMBH [DE/DE]; Zieglerstrasse 6,
52078 Aachen (DE).
- (72) Erfinder; und
- (75) Erfinder/Anmelder (nur für US): CHRISTOPH,
Thomas [DE/DE]; Schilderstrasse 42, 52080 Aachen
(DE). FRIDERICHS, Elmar [DE/DE]; Zehntweg 24,
52223 Stolberg (DE).
- (81) Bestimmungsstaaten (national): AF, AG, AI, AM, AT,
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.
- (84) Bestimmungsstaaten (regional): ARIPO-Patent (GH,
GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,
ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SI, TR),
OAPI-Patent (BI, BJ, CI, CG, CL, CM, GA, GN, GQ, GW,
ML, MR, NF, SN, TD, TG).
- Veröffentlicht:
— ohne internationalen Recherchenbericht und erneut zu
veröffentlichen nach Erhalt des Berichts
- Zur Erklärung der Zweibuchstaben-Codes und der anderen
Abkürzungen wird auf die Erklärungen ("Guidance Notes on
Codes and Abbreviations") am Anfang jeder regulären Ausgabe
der PCT-Gazette verwiesen.



WO 02/43714 A2

(54) Title: USE OF SUBSTITUTED 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR
TREATING URINARY INCONTINENCE

(54) Bezeichnung: VERWENDUNG VON SUBSTITUIERTEN 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXAN-
VERBINDUNGEN ZUR THERAPIE DER HARNINKONTINENZ

(57) Abstract: The invention relates to the use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for pro-
ducing a medicament for treating the frequent urge to pass water or urinary incontinence. The invention also relates to corresponding
medicaments and methods for treating the frequent urge to pass water or urinary incontinence.

(57) Zusammenfassung: Die Erfindung betrifft die Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexan-
verbindungen zur Herstellung eines Arzneimittels zur Behandlung von vermehrtem Harndrang bzw. Harninkontinenz sowie entspre-
chende Arzneimittel und Verfahren zur Behandlung von vermehrtem Harndrang bzw. Harninkontinenz.

Use of Substituted 6-dimethylaminomethyl-1-phenylcyclohexane Compounds for the Treatment of Urinary Incontinence

5 The present invention relates to the use of substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds as free bases and/or in the form of physiologically compatible salts for the production of a medicament for treating increased urinary urgency or urinary incontinence, as well
10 as corresponding medicaments and methods for treating increased urinary urgency or urinary incontinence.

Urinary incontinence is the involuntary passing of urine. This occurs in an uncontrolled manner if the pressure
15 within the bladder exceeds the pressure required to close the ureter. Causes may include on the one hand an increased internal bladder pressure (e.g. due to detrusor instability) resulting in urgency incontinence, and on the other hand a reduced sphincter pressure (e.g. after
20 childbirth or surgical intervention) resulting in stress incontinence. The detrusor is the collection of coarse bundles forming the multilayered muscular wall of the bladder, whose contraction leads to the voiding of urine, and the sphincter is the constrictor muscle of the urethra.
25 Mixed forms of these types of incontinence as well as so-called overflow incontinence (e.g. in the case of benign prostatic hyperplasia) or reflex incontinence (e.g. following damage to the spinal cord) occur. Further details may be found in Chutka, D.S. and Takahashi P.Y.,
30 1998, Drugs 560: 587-595.

Urinary urgency is the state of increased bladder muscle tone ending in voiding of urine (micturition) when the bladder is almost full (or when its capacity is exceeded). This muscle tone acts as a stimulus to pass urine.

5 Increased urinary urgency is understood in this connection to mean in particular the occurrence of premature or more frequent and sometimes even painful urinary urgency up to so-called dysuria. This consequently leads to a significantly increased frequency of micturition. The
10 causes may include, *inter alia*, inflammation of the bladder and neurogenic bladder disorders, as well as also bladder tuberculosis. However, all causes have not yet been elucidated.

15 Increased urinary urgency and also urinary incontinence are regarded as extremely unpleasant and there is therefore a clear need to achieve the greatest possible long-term improvement in patients affected by these medical conditions.

20 Increased urinary urgency and in particular urinary incontinence are normally treated with substances that act on the reflexes of the lower urinary tract (Wein A.J., 1998, Urology 51 (Suppl. 21): 43-47). In general these are
25 medicaments that have an inhibiting effect on the detrusor muscle, which is responsible for the internal bladder pressure. These medicaments include for example parasympatholytics such as oxybutynin, propiverine or tolterodine, tricyclic antidepressants such as imipramine,
30 or muscle relaxants such as flavoxate. Other medicaments

that in particular increase the resistance of the urethra or cervix of the bladder have affinities to α -adrenoreceptors such as ephedrine, to β -adrenoreceptors such as clenbutarol, or are hormones such as oestradiol.

5 Also, certain opioids, diarylmethylpiperazines and diarylmethylpiperidines have been described for this medical condition in WO 93/15062.

In the medical conditions that are of interest here, it should be noted that in general these involve the long-term use of medicaments and, in contrast to many situations in which analgesics are used, patients are subjected to very unpleasant but not intolerable discomfort. Accordingly in this case - even more than with analgesics - care should be taken to avoid side effects if the patient does not wish to exchange one discomfort for another. Furthermore, in the long-term treatment of urinary incontinence analgesic effects are also largely undesirable.


20 The object of the present invention was accordingly to find substances that are helpful in the treatment of increased urinary urgency or urinary incontinence and that at effective doses preferably at the same time exhibit fewer side effects and/or analgesic effects than are known from the prior art.

It has now surprisingly been found that compounds according to the general formula I have an outstanding effect on bladder function and accordingly are suitable for treating corresponding medical conditions.

Accordingly, the present invention provides for the use of a substituted 6-dimethylaminomethyl-1-phenylcyclohexane compound according to the general formula I

5

10



I

wherein

15

X is selected from OH, F, Cl, H or OC(O)R⁷ where R⁷ is selected from C₁₋₃-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted,

20

R¹ is selected from C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and

25

R⁹ to R¹³ are in each case selected independently of one another from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply

substituted; phenyl that is unsubstituted or singly or multiply substituted;

5 where R¹⁴ is selected from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or singly or multiply substituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-10 C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups may be branched or unbranched, saturated or 15 unsaturated, unsubstituted or singly or multiply substituted;

where R¹⁷ and R¹⁸ are in each case selected independently of one another from H; C₁₋₆-20 alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted; phenyl, benzyl or phenethyl that is in each case unsubstituted or singly or multiply 25 substituted,

or

R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O,
OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH,
(CH₂)₄ or OCH=CHO ring,

5 in the form of their racemates; enantiomers,
diastereomers, in particular mixtures of their
enantiomers or diastereomers, or an individual
enantiomer or diastereomer; their bases and/or salts
of physiologically compatible acids

10

for the production of a medicament for treating
increased urinary urgency or urinary incontinence.

It has surprisingly been found that the aforementioned
15 substances have a significant positive influence on certain
physiological parameters that are of importance in
increased urinary urgency or urinary incontinence, and thus
have a positive influence either on the threshold pressure,
the intercontraction interval, or on reducing the rhythmic
20 bladder contractions and/or bladder capacity. Each one of
these changes can mean a significant improvement in the
range of symptoms exhibited by affected patients.
Corresponding compounds and their production are known from
DE 195 25 137 A1.

25

Within the context of the present invention alkyl radicals
are understood to be saturated and unsaturated, branched
and unbranched hydrocarbons that may also be at least
singly substituted. Preferred alkyl radicals are methyl,
30 ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-

propinyl, methylethyl, n-butyl, sec.-butyl, tert.-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, CHF₂, CF₃ or CH₂OH.

5

Furthermore, cycloalkyl radicals within the context of this invention are understood to be saturated cyclic hydrocarbons that may also be at least singly substituted. Preferred cycloalkyl radicals are cyclopropyl, cyclobutyl, 10 cyclopentyl, cyclohexyl or cycloheptyl.

In connection with alkyl and cycloalkyl, the term substituted within the context of this invention is understood to mean the replacement of an hydrogen atom by 15 F, Cl, Br, I, NH₂, SH or OH, and "multiply substituted" is understood to mean that the substitution takes place on different as well as on the same atoms with the same or different substituents, for example triply on the same C atom as in the case of CF₃, or at different positions as in 20 the case of -CH(OH)-CH=CH=CHCl₂.

In connection with phenyl, benzyl or phenethyl, the term substituted is preferably understood to mean substitution with H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁹, OCF₃, 25 SR¹⁹, NH₂, CONH₂, SOCH₃, SOCF₃, SO₂CH₃, SO₂CF₃, CN, COOR¹⁹, NO₂; C₁₋₆-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted; phenyl that is unsubstituted;

where R¹⁹ is selected from C₁₋₆-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted; or C₃₋₇-cycloalkyl.

5

Suitable salts within the meaning of the present invention and in each of the claimed uses are salts of the respective active ingredient with inorganic or organic acids and/or a sugar replacement such as saccharine, cyclamate or
10 acesulfam. However, the hydrochloride is particularly preferred.

In this connection it is preferred to use compounds according to formula I in which X is selected from

15

OH, F, Cl, OC(O)CH₃ or H, preferably OH, F or H.

Furthermore, it is also preferred to use compounds according to formula I in which R¹ is selected from

20

C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F, preferably OH, CF₃ or CH₃.

It is furthermore preferred to use compounds according to
25 formula I in which R⁹ to R¹³, wherein three or four of the radicals R⁹ to R¹³ must correspond to H, are selected independently of one another from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl that is
30 saturated and unsubstituted, branched or

unbranched; OR¹⁴ or SR¹⁴ where R¹⁴ is selected from C₁₋₃-alkyl that is saturated and unsubstituted, branched or unbranched;

5 preferably H, Cl, F, OH, CF₂H, CF₃, OCH₃ or SCH₃

or R¹² and R¹¹ form a 3,4-OCH=CH ring

10 in particular those in which,

if R⁹, R¹¹ and R¹³ correspond to H, then one of R¹⁰ or R¹² also corresponds to H, while the other is selected from:

15 Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, preferably OH, CF₂H, OCH₃ or SCH₃,

or,

20 if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, preferably Cl, then one of R¹⁰ or R¹² also corresponds to H, while the other corresponds to OH, OCH₃, Cl or F, preferably Cl,

25 or,

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is selected from CF₃, CF₂H, Cl or F, preferably F,

30

10

or,

if R^{10} , R^{11} and R^{12} correspond to H, one of R^9 or R^{13} also corresponds to H, while the other is selected from OH, OC_2H_5 or OC_3H_7 .

5

Also preferred is the use of compounds according to formula I wherein R^9 , R^{11} and R^{13} correspond to H, one of R^{10} or R^{12} also corresponds to H, while the other is selected


10 from:

Cl, F, OH, SH, CF_2H , CF_3 , OR^{14} or SR^{14} , preferably OH or OR^{14} , in particular OH or OC_{1-3} -alkyl, preferably OH or OCH_3 .

15 It is also preferred if compounds according to formula I in the form of the diastereomers with the relative configuration Ia

20

25



Ia

are present, in particular in mixtures with a higher proportion of this diastereomer compared to the other diastereomer or as pure diastereomer.

5 It is furthermore preferred if the compounds of the formula I are used in the form of the (+) enantiomer, in particular in mixtures with a higher proportion of the (+) enantiomer compared to the (-) enantiomer of a racemic compound or as pure (+) enantiomer.

10

In general, with the preferred use of the (+) enantiomer a smaller proportion of (-) enantiomer compared to the (+) enantiomer is also acceptable and may - but need not be - involved in the use according to the invention.

15

It is particularly preferred to use a compound selected from the following group:

- 20 • (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxyphenyl)-cyclohexane-1,3-diol,
- 25 • (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methylcyclohexyl)-phenol, or

- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethylcyclohexyl)-phenol


preferably as hydrochloride.

5

Also, if the uses according to the invention produce only slight side effects, it may for example also be advantageous in order to avoid certain types of dependence to use, in addition to compounds according to the general formula I, also morphine antagonists, in particular naloxone, naltrexone and/or levallorphan.

The invention also comprises medicaments for treating increased urinary urgency or urinary incontinence that contain as active ingredient at least one substituted 6-dimethylaminomethyl-1-phenylcyclohexane compound according to the general formula I

20



25

wherein

X is selected from OH, F, Cl, H or OC(O)R⁷ where R⁷ is selected from C₁₋₃-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted,

30

R¹ is selected from C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and

5 R⁹ to R¹³ are in each case selected independently of one another from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl that is branched or unbranched, saturated or
10 unsaturated, unsubstituted or singly or multiply substituted; phenyl that is unsubstituted or singly or multiply substituted;

where R¹⁴ is selected from C₁₋₆-alkyl;
15 pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or singly or multiply substituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the
20 radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups may be branched or unbranched, saturated or
25 unsaturated, unsubstituted or singly or multiply substituted;

where R¹⁷ and R¹⁸ are in each case selected independently of one another from H; C₁₋₆-alkyl that is branched or unbranched,
30

5 saturated or unsaturated, unsubstituted or
singly or multiply substituted; phenyl,
benzyl or phenethyl that is in each case
unsubstituted or singly or multiply
substituted,

or

10 R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O ,
 OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$,
 $(CH_2)_4$ or $OCH=CHO$ ring,

15 in the form of their racemates; enantiomers,
diastereomers, in particular mixtures of their
enantiomers or diastereomers, or an individual
enantiomer or diastereomer; their bases and/or salts
of physiologically compatible acids

20 as well as optionally additives and/or auxiliary
substances.

Suitable salts within the context of the present invention
and in each of the claimed uses are salts of the respective
active ingredient with inorganic or organic acids and/or a
25 sugar substitute such as saccharine, cyclamate or
acesulfam. However, the hydrochloride is particularly
preferred.

30 Suitable additives and/or auxiliary substances within the
context of the present invention are all substances known

to the person skilled in the art from the prior art for achieving the preparation of galenical formulations. The choice of these auxiliary substances as well as the amounts thereof to be used depend on whether the medicament is to be administered orally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally or topically. For oral application preparations in the form of tablets, chewable tablets, sugar-coated pills, capsules, granules, drops, juices or syrups are suitable, while for parenteral, topical and inhalative application solutions, suspensions, readily reconstitutable dry preparations as well as sprays are suitable. A further possible form of application are suppositories for rectal use. The use in a depôt form, in dissolved form, in a carrier film or a plaster, optionally with the addition of agents promoting penetration of the skin, are examples of suitable percutaneous application forms. Examples of auxiliary substances and additives for oral application forms are disintegrants, lubricants, binders, fillers, mould release agents, optionally solvents, taste enhancers, sugars, in particular excipients, diluents, colourants, antioxidants, etc. For suppositories there may be used *inter alia* waxes or fatty acid esters, and for parenteral application agents there may be used excipients, preservatives, suspension auxiliaries, etc. The amounts of active ingredient to be administered to the patient vary depending on the patient's weight, on the type of application and the severity of the medical condition. The compounds according to the invention may be employed in delayed release form in preparations for oral, rectal or percutaneous use.

Corresponding retard formulations, in particular in the form of a "once daily" preparation that has to be taken only once a day, are particularly preferred for use in the medical condition covered by the invention.

5

Also preferred are medicaments that contain at least 0.05 to 90.0% of the active ingredient, in particular low effective dosages in order to avoid side effects or analgesic effects. Normally 0.1 to 5000 mg/kg, in particular 1 to 500 mg/kg and preferably 2 to 250 mg/kg body weight of at least one compound of the formula I are administered. However, the administration of 0.01 to 5 mg/kg, preferably 0.03 to 2 mg/kg and in particular 0.05 to 1 mg/kg body weight is also preferred and customary.

15

Auxiliary substances may for example include the following: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, sucrose, dextrose, molasses, starch, modified starch, gelatins, sorbitol, inositol, mannitol, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, cellulose acetate, shellac, cetyl alcohol, polyvinylpyrrolidone, paraffins, waxes, natural and synthetic gums, gum arabic, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glyceryl stearate, sodium lauryl sulfate, edible oils, sesame oil, coconut oil, groundnut oil, soy bean oil, lecithin, sodium lactate, polyoxyethylene fatty acid esters and polyoxypropylene fatty acid esters, sorbitan fatty acid esters, sorbic acid,

30

benzoic acid, citric acid, ascorbic acid, tannic acid,
sodium chloride, potassium chloride, magnesium chloride,
calcium chloride, magnesium oxide, zinc oxide, silicon
dioxide, titanium oxide, titanium dioxide, magnesium
5 sulfate, zinc sulfate, calcium sulfate, potassium
carbonate, calcium phosphate, dicalcium phosphate,
potassium bromide, potassium iodide, talcum, kaolin,
pectin, crospovidone, agar and bentonite.

- 10 The medicaments and pharmaceutical compositions according
to the invention are produced with the aid of agents,
equipment, methods and processes well known in the prior
art for pharmaceutical formulations, such as are described
for example in "Remington's Pharmaceutical Sciences", Editor
15 A.R. Gennaro, 17th Edition, Mack Publishing Company, Easton,
Pa. (1985), in particular in Part 8, Chapters 76 to 93.

Thus for example, for a solid formulation such as a tablet
the active ingredient of the medicament, i.e. a compound of
20 the general structure I or one of its pharmaceutically
acceptable salts, may be granulated with a pharmaceutical
carrier, for example conventional tablet constituents such
as maize starch, lactose, sucrose, sorbitol, talcum,
magnesium stearate, dicalcium phosphate or pharmaceutically
25 acceptable gums, and pharmaceutical diluents, such as for
example water, in order to form a solid composition that
contains a compound according to the invention or a
pharmaceutically acceptable salt thereof in homogeneous
distribution. A homogeneous distribution is understood
30 here to mean that the active ingredient is uniformly

distributed over the whole composition so that the latter can be subdivided without any difficulty into equally effective unit dose forms such as tablets, pills or capsules. The solid composition is then subdivided into
5 unit dose forms. The tablets or pills of the medicament according to the invention or of the compositions according to the invention may also be coated or compounded in another way in order to prepare a dose form with a delayed-release action. Suitable coating agents include *inter alia*
10 polymeric acids and mixtures of polymeric acids with materials such as for example shellac, cetyl alcohol and/or cellulose acetate.

Also, if the medicaments according to the invention exhibit
15 only slight side effects it may for example be advantageous in order to avoid specific forms of dependence to use in addition to the compounds according to the general formula I also morphine antagonists, in particular naloxone, naltrexone and/or levallorphan.

20 Preferred are medicaments in which compounds according to general formula I are used, in which X is selected from

25 OH, F, Cl, OC(O)CH₃ or H, preferably OH, F or H, in particular OH.

Also preferred are medicaments in which compounds according to the general formula I are used in which R¹ is selected from

30

C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F,
preferably OH, CF₃ or CH₃.

It is furthermore preferred if in the medicaments according
5 to the invention compounds according to the general
formula I are used in which R⁹ to R¹³, wherein three or four
of the radicals R⁹ to R¹³ must correspond to H, are selected
independently of one another from

10 H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl that is
saturated and unsubstituted, branched or
unbranched; OR¹⁴ or SR¹⁴ where R¹⁴ is selected from
C₁₋₃-alkyl that is saturated and unsubstituted,
branched or unbranched;

15 preferably H, Cl, F, OH, CF₂H, CF₃, OCH₃ or
SCH₃

or R¹² and R¹¹ form a 3,4-OCH=CH ring,

20 in particular characterised in that

if R⁹, R¹¹ and R¹³ correspond to H, then one of R¹⁰
or R¹² also corresponds to H, while the other is
25 selected from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, preferably
OH, CF₂H, OR¹⁴ or SCH₃, in particular OH or
OC₁₋₃-alkyl, preferably OH or OCH₃,

30

or,

5 if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, preferably Cl, then one of R¹⁰ or R¹² also corresponds to H, while the other corresponds to OH, OCH₃, Cl or F, preferably Cl,

or,

10 if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is selected from CF₃, CF₂H, Cl or F, preferably F,

or,


15 if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H, while the other is selected from OH, OC₂H₅ or OC₃H₇.

Also preferred are medicaments in which compounds according
20 to the general formula I are used, wherein R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H, while the other is selected from:

25 Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, preferably OH or OR¹⁴, in particular OH or OC₁₋₃-alkyl, preferably OH or OCH₃.

It is furthermore preferred if in the medicaments according to the invention compounds according to the general

formula I are contained that are present in the form of the diastereomers with the relative configuration Ia



15 in particular in mixtures with a higher proportion of this diastereomer compared to the other diastereomer, or as pure diastereomer.

20 It is furthermore preferred if in the medicaments according to the invention compounds according to the general formula I are contained that are present in the form of the (+) enantiomer, in particular in mixtures with a higher proportion of the (+) enantiomer compared to the (-) enantiomer of a racemic compound or as pure (+) enantiomer.

25 Generally, with the preferred use of the (+) enantiomer a smaller proportion of (-) enantiomer compared to the (+) enantiomer is also acceptable and may - but need not be - contained in the medicaments according to the invention.

30 Particularly preferred are medicaments according to the invention that contain at least one compound selected from the following group:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- 5 • (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxyphenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
- 10 • (+)-(1R,3R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methylcyclohexyl)-phenol, or
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethylcyclohexyl)-phenol

15 preferably as hydrochloride.

The invention also provides a process for treating increased urinary urgency or urinary incontinence, in which the substituted 6-dimethylaminomethyl-1-phenylcyclohexane
20 compounds according to the invention of the general formula I are used in the form of their racemates; enantiomers, diastereomers, in particular mixtures of their enantiomers or diastereomers, or in the form of an individual enantiomer or diastereomer; as free base and/or in the form
25 of physiologically compatible salts.

The following examples serve to illustrate the invention without however restricting the subject matter of the invention.

30

Examples**Example 1: List of tested substances:**

- 5 The following is a list of the compounds tested as regards their effectiveness:

Name	Cmpd. No.
(1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, hydrochloride	24
(+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, hydrochloride	25
(1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxyphenyl)-cyclohexane-1,3-diol, hydrochloride	26
(1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, hydrochloride	27
(+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methylcyclohexyl)-phenol, hydrochloride	28
(1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethylcyclohexyl)-phenol, hydrochloride	29

Example 2: Cystometry tests on conscious fresh rats

10

Cystometry investigations were carried out on fresh female Sprague-Dawley rats according to the method of Ishizuka et al. ((1997), Naunyn-Schmiedeberg's Arch. Pharmacol. 355: 787-793). Three days after implantation of bladder and

15

venous catheters the animals were investigated in the conscious state while freely moving. The bladder catheter

was connected to a pressure gauge and an injection pump. The animals were placed in metabolic cages that enable the volume of urine to be measured. Physiological saline solution was infused (10 ml/hour) into the emptied bladder and the bladder pressure and volume of urine were continuously recorded. After a stabilisation phase a 20-minute phase was recorded that was characterised by normal, reproducible micturition cycles. The following parameters among others were measured:

10

- threshold pressure TP, bladder pressure immediately before micturition,
- bladder capacity BC, residual volume after prior micturition plus volume of infused solution during the filling phase,
- intercontraction interval ICI, i.e. the time interval between consecutive micturition.

15

An increase in the threshold pressure (TP) indicates an important therapeutic effect in one of the medical conditions covered by the invention. Also, the intercontraction interval (ICI) is an important parameter for measuring the physiological effectiveness of a substance in the treatment of urinary incontinence, as is the bladder capacity (BC). In this connection, on account of the widely differing causes of the symptoms of these disease patterns it is not necessary to influence positively all three parameters in order for a medicament to be effective. It is therefore completely sufficient if a positive effect is demonstrated in only one of these

25

30

parameters in order for the medicament to be of use in urinary incontinence or increased urinary urgency.

After recording three reproducible micturition cycles to
5 provide a baseline value, the test substances **24** (1.0; 3.0;
5.0 mg/kg), **25** (1.5 mg/kg) and **26** (3.0 mg/kg) in a vehicle
comprising 0.9% NaCl were applied intravenously and the
effect on the cystometric parameters was recorded at 90 to
120 minutes. In the effect maximum the mean value of 3
10 micturition cycles was determined and recorded as a
percentage change compared to the baseline value (Table 1).

Compound: (Concentration)	TP Threshold Pressure	BC Bladder Capacity	ICI Inter- Contraction Interval
24			
1.0 mg/kg iv (n=7)	+44.0%***	-8.0%	-15%**
3.0 mg/kg iv (n=8)	+94.0%***	-16.0%*	-16%*
5.0 mg/kg iv (n=8)	+69.0%*	-26.0%	-21.2%
25			
1.5 mg/kg iv (n=8)	+62.0%*	-14.0%*	-9.0%
26			
3.0 mg/kg iv (n=7)	+86.0%***	+29.0%***	+27.0%*

Table 1: Influencing of the cystometric parameters by the test substances (change compared to the baseline value [%]); n corresponds to the number of experimental animals.

The investigated substances exhibit a positive effect on the bladder regulation and are therefore suitable for treating urinary incontinence.

10

Example 3. Cystometry investigations in narcotised fresh rats

The cystometric investigation was carried out on fresh female rats according to the method of Kimura et al. (Kimura et al., 1996, Int. J. Urol. 3: 218-227). The abdomen of narcotised ventilated rats is opened and the ureter is ligated. The urine is drawn off from the kidneys. A catheter is inserted into the bladder and

15

secured in place. Saline is infused by means of an infusion pump via the catheter into the bladder until this exhibits rhythmic spontaneous activity in the form of contractions that can be recorded via a connected pressure recorder. The test substance is applied intravenously in a cumulative manner after stable starting values were reached. An effect on the bladder function is manifested by the suppression of the spontaneous contractions. The disappearance of the contractions over a period of 10 minutes serves as a parameter for their suppression.

With all the substances listed there was a measurable suppression of the spontaneous contractions in rats, Table 2 showing the mean value of the lowest dose from at least two experiments, in which contractions disappeared for the first time over a period of 10 minutes.

Compound No.	Lowest Dose [mg/kg]
27	115 (n=2)
28	16.7 (n=3)
29	23.3 (n=3)

Table 2: (n corresponds to the number of the experiments involved in the value)


The investigated substances exhibit a positive effect on bladder regulation and are thus suitable for treating urinary incontinence.

Example 4: Parenteral application form

1 g of the compound **26** is dissolved at room temperature in
1 l of water for injection purposes and is then adjusted to
5 isotonic conditions by adding NaCl.

The claims defining the invention are as follows:

1. Use of a substituted 6-dimethylaminomethyl-1-phenylcyclohexane compound according to the general formula I



I

wherein

X is selected from OH, F, Cl, H or OC(O)R⁷ where R⁷ is selected from C₁₋₃-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted,

R¹ is selected from C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and

R⁹ to R¹³ are in each case selected independently of one another from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, Sh, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃, SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted; phenyl that is unsubstituted or singly or multiply substituted;

where R¹⁴ is selected from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or singly or multiply substituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups may be branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted;

where R¹⁷ and R¹⁸ are in each case selected independently of one another from H; C₁₋₆-alkyl that is branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted; phenyl, benzyl or phenethyl that is in each case unsubstituted or singly or multiply substituted,

or

R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O, OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH, (CH₂)₄ or OCH=CHO ring,

in the form of their racemates; enantiomers, diastereomers, in particular mixtures of their enantiomers or diastereomers, or an individual enantiomer or diastereomer; their bases and/or salts of physiologically compatible acids

for the production of a medicament for treating increased urinary urgency or urinary incontinence.

2. Use according to claim 1, wherein X is selected from OH, F, Cl, OC(O)CH₃ or H, preferably OH, F or H, in particular OH.
3. Use according to claim 1 or claim 2, wherein R¹ is selected from C₁₋₄-alkyl, CF₃, OH, O-C_{1,4}-alkyl, Cl or F, preferably OH, CF₃ or CH₃.
4. Use according to any one of claims 1 to 3, wherein R⁹ to R¹³, wherein three or four of the radicals R⁹ to R¹³ must correspond to H, are selected independently of one another from

H, Cl, F, OH, CF₂H, CF₃ or C_{1,4}-alkyl that is saturated and unsubstituted, branched or unbranched; OR¹⁴ where R¹⁴ is selected from C₁₋₃-alkyl that is saturated and unsubstituted, branched or unbranched;

preferably H, Cl, F, OH, CF₂H, CF₃, OCH₃ or SCH₃
or R¹² and R¹¹ form a 3,4-OCH=CH ring.

5. Use according to claim 4 wherein if R⁹, R¹¹ and R¹³ correspond to H, then one of R¹⁰ or R¹² also corresponds to H, while the other is selected from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, preferably OH, CF₂H, OR¹⁴ or SCH₃, in particular OH or OC₁₋₃-alkyl, preferably OH or OCH₃,

or,

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, preferably Cl, then one of R¹⁰ or R¹² also corresponds to H, while the other corresponds to OH, OCH₃, Cl or F, preferably Cl,

or,

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is selected from CF₃, CF₂H, Cl or F, preferably F,

or,


if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H, while the other is selected from OH, OC₂H₅ or OC₃H₇.

6. Use according to any one of claims 1 to 5, wherein R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H, while the other is selected from:

31

Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, preferably OH or OR¹⁴, in particular OH or OC₁₋₃-alkyl, preferably OH or OCH₃.

7. Use according to any one of claims 1 to 6, wherein compounds of the formula I are present in the form of the diastereomers with the relative configuration Ia



Ia

8. Use according to claim 7 wherein the compounds of formula I are present in mixtures with a higher proportion of this diastereomer compared to the other diastereomer or as pure diastereomer.

9. Use according to any one of claims 1 to 8, wherein the compounds of the formula I are employed in the form of the (+) enantiomer, in particular in mixtures with a higher proportion of the (+) enantiomer compared to the (-) enantiomer of a racemic compound, or as pure (+) enantiomer.

10. Use according to any one of claims 1 to 9, wherein a compound selected from the following group is used:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
 - (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
 - (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxyphenyl)-cyclohexane-1,3-diol,
 - (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol,
 - (+)-(1R,3R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methylcyclohexyl)-phenol,
- or
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethylcyclohexyl)-phenol preferably as hydrochloride.

2002223688 19 May 2006

32

11. Use according to claim 1, said use being substantially as hereinbefore described with reference to example 2 or example 4.

Dated 17 May, 2006

Grunenthal GmbH

5

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

[R:\LIBZ\07010speci.doc: NJC